Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury.
Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.
18-80 years old
End-stage liver disease
Signed informed consent
Tumours of the liver or other organs
Liver transplantation recipients
Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
Other diseases that may seriously affect the survival
Parallel
Infusion of umbilical cord-mesenchymal stem cells through peripheral veins
Other interventionUmbilical cord-mesenchymal stem cells injected through peripheral veins
Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
Other interventionUmbilical cord-mesenchymal stem cells injected through hepatic artery
Survival rate
Number of subjects surviving after 24 weeks
Changes in Model for End-Stage Liver Disease (MELD) score
The Model for End-Stage Liver Disease (MELD) score ranges from 6 to 40, with higher values indicating more severe liver dysfunction and an increased risk of mortality.
Changes in Child-Pugh score
The Child-Pugh score is categorized into class A (5-6 points), class B (7-9 points), and class C (≥10 points), reflecting progressive liver disease severity. Higher Child-Pugh scores are associated not only with increased mortality risk but also with a significantly higher incidence of complications, such as gastrointestinal bleeding and infections.
Incidence of hepatic decompensation events
Number of patients who developed gastrointestinal bleeding, ascites, and hepatic encephalopathy
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
